Navigation Links
FDA Approves VYVANSE(TM) (lisdexamfetamine dimesylate), the First and Only Once-Daily Prodrug Stimulant to Treat ADHD in Adults
Date:4/23/2008

may cause sudden death and serious cardiovascular adverse events. These events have also been reported rarely with amphetamine use.

VYVANSE was generally well tolerated in clinical studies. The most common side effects reported in studies of VYVANSE were: children - decreased appetite, difficulty falling asleep, stomachache, and irritability; adult - decreased appetite, difficulty falling asleep, and dry mouth.

Aggression, new abnormal thoughts/behaviors, mania, growth suppression, worsening of motion or verbal tics, and Tourette's syndrome have been associated with use of drugs of this type. Tell the doctor if you or your child has blurred vision while taking VYVANSE.

Shire PLC

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe. Shire believes that a carefully selected portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's website: http://www.shire.com.

"Safe Harbor" Statement Under the Private Securities Litigation Reform Act of 1995

Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Shire's r
'/>"/>

SOURCE Shire PLC
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Maryland Approves Medicaid Reimbursement for ActiPatch(R)
2. Healthcare Coalition Approves Tools to Improve Patient Safety During Transitions of Care
3. Medicare Approves in Home Sleep Apnea Testing
4. 3SBio Inc. Approves Share Repurchase Program
5. Baxters Board of Directors Approves New Share Repurchase Authorization of $2 Billion
6. FDA Approves PRISTIQ(TM) for the Treatment of Adult Patients with Major Depressive Disorder
7. FDA Approves INTELENCE(TM) (etravirine) for HIV Combination Therapy
8. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
9. FDA Approves New Mechanism of Action Labeling for Ranexa(R)
10. FDA Approves Diovan(R) for Treatment of High Blood Pressure in Children
11. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) as the First Medication for Add-On Treatment of Major Depressive Disorder (MDD)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2015)... , April 23, 2015  Metanome, Inc., an ... the company has changed its name to Diversigen, ... positioning as the single commercial source for the ... capitalize on the diverse opportunities of the microbiome. ... Diversigen accepts – including those that are difficult ...
(Date:4/23/2015)... 2015 Delpor, Inc. (Delpor), a biotechnology ... United States Patent and Trademark Office has issued 2 ... technology. US Pat. No. 8,986,727 was issued on ... delivery device for the sustained release of therapeutic ... the sustained (zero-order) release of large and small molecules ...
(Date:4/22/2015)... April 22, 2015   MPIRICA Health Inc. ... $1.6M in Series A financing from the McQuinn ... helps accelerate consumer and employer awareness of MPIRICA.com, ... at over 4,800 U.S. hospitals. "As ... probably very concerned about choosing the hospital and ...
(Date:4/22/2015)... (PRWEB) April 22, 2015 ... medical devices market witnessed tremendous growth primarily ... and increasing government support with increased nanotechnology ... , Request Customization: , http://www.marketsandmarkets.com/requestCustomization.asp?id=65048077 ... medical devices market is segmented on the ...
Breaking Biology Technology:Metanome Announces Corporate Name Change to Diversigen 2Delpor, Inc. Announces the Issuance of 2 New US Patents Based on its Nanopore Technology which Enables the Sustained Release of Drugs from a Small Implant Device 2Delpor, Inc. Announces the Issuance of 2 New US Patents Based on its Nanopore Technology which Enables the Sustained Release of Drugs from a Small Implant Device 3MPIRICA Health Inc. Secures $1.6M to Promote FICO-Like Quality Scores for Surgeries 2Nanotechnology-based Medical Devices Market to Reach Around $8.5 billion by 2019 - Published by MarketsandMarkets 2Nanotechnology-based Medical Devices Market to Reach Around $8.5 billion by 2019 - Published by MarketsandMarkets 3
... 11 Altogen Biosystems,( http://www.altogen.com ) announced ... Las Vegas, NV, Altogen Custom Services focus ... Interference (RNAi) services, generation of stably-expressing cell,lines, ... the company will draw upon their unique ...
... affordable and accessible to all researchers, HUNTSVILLE, ... that Harvard Medical School and the University of ... Each University,purchased access to whole genome human and ... and distributed by Open Biosystems., (Logo: ...
... China-based R&D and production platform and Datascope,s strong US-based ... direct sales and service network, Provides powerful ... ... SHENZHEN, China, March 11 /Xinhua-PRNewswire-FirstCall/ -- Mindray,Medical International Limited (NYSE: ...
Cached Biology Technology:Altogen Biosystems Launches Custom Biotechnology Research Services: Generation of Stable Cell Lines and RNAi Cell Transfection Services 2Open Biosystems' Open Access RNAi Program Adopted by Harvard Medical School and University of North Carolina 2Mindray to Acquire Datascope's Patient Monitoring Business for US$202 million 2Mindray to Acquire Datascope's Patient Monitoring Business for US$202 million 3Mindray to Acquire Datascope's Patient Monitoring Business for US$202 million 4Mindray to Acquire Datascope's Patient Monitoring Business for US$202 million 5Mindray to Acquire Datascope's Patient Monitoring Business for US$202 million 6
(Date:4/20/2015)... , April 20, 2015 Huntington Memorial Hospital ... to implant a new miniaturized, wireless monitoring sensor to ... the first and only FDA-approved heart failure monitoring device ... when used by physicians to manage heart failure. ... is implanted in the pulmonary artery (PA) during a ...
(Date:4/14/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... on the growing mobile commerce market, announces that its ... New York Design Awards under the category  ,Product Design ... Design Awards are part of a global multi-disciplinary awards ... from the marketplace, industry and judging panel. Winners will ...
(Date:4/9/2015)... April 9, 2015 Synaptics Inc. (NASDAQ: SYNA ... today that it will report financial results for the ... 2015, after the close of market. The company will ... at 2:00 p.m. PT (5:00 p.m. ET), during which ... participate on the live call, analysts and investors should ...
Breaking Biology News(10 mins):Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3Synaptics to Report Third Quarter Results on April 23 2
... popular designer cannabis products called "Spice" or "K2" have ... researchers is reporting progress toward understanding what makes them ... Analytical Chemistry , describes development of a method ... thousands of young adults and teens who end up ...
... for Parkinson,s Research and Shake It Up Australia Foundation ... Institute of Medical Research to look at the role ... non-coding RNAs are complex molecules, produced from a DNA ... body. Unlike conventional genes, they do not make proteins ...
... of strong design competence and cutting-edge cellulose-based technologies ... aim is for fibre from wood-based biomass to ... and polyester production, which consumes oil. A research ... Finland, Aalto University and Tampere University of Technology ...
Cached Biology News:Garvan Institute receives grant to research role of long non-coding RNAs in Parkinson's disease 2Finland to lead the way as a designer of cellulose-based products 2Finland to lead the way as a designer of cellulose-based products 3
Unit Definition: 1 U corresponds to the amount of enzyme which produces 1 mol protons per minute at pH 5.5 and 30C (peptin from citrus peel, Fluka-No. 76280, as substrate)...
... Kinase. This product is expected ... other mammalian species but has not ... a single precipitin line against partially ... shown to react with all forms ...
Rabbit polyclonal to Somatostatin 28 ( Abpromise for all tested applications). entrezGeneID: 6750 SwissProtID: P61278...
... tube handling and reagent dispensing Holds: ... - 96 x 0.3ml U-bottom Omnistrips ... Non-Skirted Plate - Thermo-Fast® 96 Semi-Skirted Plate ... Multiple workstations can be securely stacked Can be stored ...
Biology Products: